Work

SAT0177 Real-world interruptions in janus kinase inhibitor therapy observed among biologic-naÏve and biologic-experienced rheumatoid arthritis patients

Year: 2018

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2018-eular.3456

Authors: B. Chastek, E. Koep, U.G. Mallya, A. Cockerham, J. Choi, S. Boklage, D.E. Furst

Institutions: Optum (United States), Sanofi (United States), Regeneron (United States), University of California, Los Angeles, University of Washington, University of Florence

Language: English

Topic: Rheumatoid Arthritis Research and Therapies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Pfizer, Sanofi, Regeneron Pharmaceuticals, Genentech

OpenAlex ID: W2886847252

Cites: 2

Cited by: 1

Related to: 10